Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia by Marković-Sovtić Gordana et al.
Vojnosanit Pregl 2013; 70(11): 1029–1033. VOJNOSANITETSKI PREGLED Strana 1029
Correspondence to: Gordana Markoviý-Sovtiý, Institute for Mother and Child Health Care of Serbia “Dr Vukan þupiý”, Radoja Dakiýa
6, 11 070, Belgrade, Serbia. Phone/Fax.: +381 11 2606 886. E-mail: ljgmarkovic@beotel.rs
ORIGINAL ARTICLE UDC: 616-053.31::616.15-08
DOI: 10.2298/VSP1311029M
Use of intravenous immunoglobulin in neonates with haemolytic
disease and immune thrombocytopenia
Primena intravenskih imunoglobulina kod novoroÿenþadi sa hemoliznom
bolesti i imunskom trombocitopenijom
Gordana Markoviü-Sovtiü, Borisav Jankoviü, Zorica Rakonjac, Jelena Martiü,
Katarina Pejiü
Institute for Mother and Child Health Care of Serbia, “Dr Vukan ýupiü”,
Belgrade, Serbia
Abstract
Background/Aim. Intravenous immunoglobulin is a
blood product made of human polyclonal immunoglobulin
G. The mode of action of intravenous immunoglobulin is
very complex. It is indicated in treatment of neonatal im-
mune thrombocytopenia and haemolytic disease of the
newborn. The aim of the study was to present our experi-
ence in the use of intravenous immunoglobulin in a group
of term neonates. Methods. We analysed all relevant clini-
cal and laboratory data of 23 neonates who recieved intra-
venous immunoglobulin during their hospitalization in
Neonatal Intensive Care Unit of Mother and Child Health
Care Institute over a five year period, from 2006. to 2010.
Results. There were 11 patients with haemolytic disease of
the newborn and 12 neonates with immune thrombocyto-
penia. All of them recieved 1–2 g/kg intravenous immuno-
globulin in the course of their treatment. There was no ad-
verse effects of intravenous immunoglobulin use. The use
of intravenous immunoglobulin led to an increase in platelet
number in thrombocytopenic patients, whereas in those
with haemolytic disease serum bilirubin level decreased sig-
nificantly, so that some patients whose bilirubin level was
very close to the exchange transfusion criterion, avoided
this procedure. Conclusion. The use of intravenous immu-
noglobulin was shown to be an effective treatment in re-
ducing the need for exchange transfusion, duration of
phototherapy and the length of hospital stay in neonates
with haemolytic disease. When used in treatment of neona-
tal immune thrombocytopenia, it leads to an increase in the
platelet number, thus decreasing the risk of serious compli-
cations of thrombocytopenia.
Key words:
thrombocytopenia, neonatal alloimmune; anemia,
hemolytic; infant, newborn; immunoglobulins,
intravenous.
Apstrakt
Uvod/Cilj. Intravenski imunoglobulini su preparat humanih
imunoglobulina G dobijenih iz plazme zdravih davalaca. Me-
hanizam delovanja intravenskih imunoglobulina veoma je
složen. Njihova primena je indikovana u leÿenju hemolizne
bolesti i imunskoj trombocitopeniji novoroĀenÿeta. Cilj rada
bio je prikaz sopstvenog iskustva u primeni intravenskih imu-
noglobulina u grupi terminske novoroĀenÿadi.  Metode.
Analizirani su anamnestiÿki podaci, kliniÿki nalazi i laborato-
rijski rezultati 23 novoroĀenÿeta koji su u periodu od 2006.
do 2010. dobijali intravenske imunoglobuline tokom hospita-
lizacije u neonatalnoj intenzivnoj nezi Instituta za majku i
dete Srbije „Dr Vukan þupiý“. Rezultati. Kod 11 novoro-
Āenÿadi indikacija za primenu intravenskih imunoglobulina
bila je hemolizna bolest novoroĀenÿeta, dok je 12 novoro-
Āenÿadi imalo imunsku trombocitopeniju. Kod svih bolesnika
primenjena je doza od 1 do 2 g/kg telesne mase intravenskih
imunoglobulina. Nisu registrovane komplikacije primenjene
terapije. Kod novoroĀenÿadi sa hemoliznom bolešýu došlo je
do znatnog sniženja nivoa bilirubina, što je omoguýilo da naj-
veýi broj bolesnika izbegne eksangvinotransfuziju. Primena
intravenskih imunoglobulina dovela je do znaÿajnog porasta
broja trombocita kod bolesnika sa imunskom trombocitope-
nijom. Zakljuÿak. Primena intravenskih imunoglobulina vrlo
je efikasna za snižavanje potrebe za eksagvinotransfuzijom, za
skraýenje trajanja fototerapije i skraýenju trajanja hospitaliza-
cije kod novoroĀenÿadi sa hemoliznom bolešýu. Kod novo-
roĀenÿadi sa imunskom trombocitopenijom primena intra-
venskih imunoglobulina dovodi do znaÿajnog porasta broja
trombocita, snižavajuýi time rizik od potencijalno ozbiljnih
komplikacija trombocitopenije.
Kljuÿne reÿi:
trombocitomenija, neonatalna, aloimunska; anemija,
hemolitiÿka; novoroĀenÿe; imunoglobulini,
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Introduction
Intravenous immunoglobulin (IVIG) is a blood product
made of human polyclonal immunoglobulin G (IgG). It is
obtained from plasma of thousands of healthy blood donors,
therefore providing a great variety of antibodies. It contains
more than 95% of unmodified immunoglobulin G and some
traces of immunoglobulin A and immunoglobulin M. It has
been first used in treatment of primary immunodeficiency
and nowadays is used in treatment of many hematological,
neurological, rheumatic and dermatological diseases 
1. The
mode of action of immunoglobulin is complex and it in-
cludes modulation of Fc-receptor mediated phagocytosis,
complement binding and prevention of membrane attack
complex formation, inhibition of some cytokines, down-
regulation of antibody production etc. 
1, 2. According to well-
established recommendations, the indications for use of IVIG
in neonates are: haemolytic disease of the newborn (HDN),
immune thrombocytopenia and fetal hydrops caused by
PARVO B19 virus 
3. The use of IVIG in prevention and
treatment of neonatal sepsis, especially in preterm neonates,
is still controversial 
4, 5.
The aim of this study was to present our experience in
the use of IVIG in a group of term neonates.
To our knowledge, this is the first presentation of na-
tional experience in the use of IVIG in neonates with hemo-
lytic disease of the newborn and neonates with immune
thrombocytopenia.
Methods
Over a five year period, from 2006 to 2010, intravenous
immunoglobulin was administered in the Neonatal Intensive
Care Unit (NICU) of Mother and Child Health Care Institute
of Serbia “Dr. Vukan ýupiü” in the treatment of 23 term
neonates. This presentation encompasses two groups of pa-
tients: neonates with haemolytic disease of the newborn and
neonates with immune thrombocytopenia. All the data con-
cerning pregnancy, perinatal history, management in imme-
diate postnatal period as well the treatment received prior to
admission to the NICU, were collected from medical records.
We obtained written consent from the parents for blood sam-
ple collection of the neonates.
The group I of patients included of neonates with iso-
immune haemolytic disease (HD) due to Rh or ABO incom-
patibility between the blood group of the mother and the
newborn, proven by the positive direct Coombs test, indirect
hypebilirubinemia and increased reticulocyte count. Hyper-
bilirubinemia was considered significant if phototherapy
and/or exchange transfusion (ET) was required 
6. Laboratory
investigations included: serum bilirubin level (total and di-
rect), direct Coombs test, full blood count with reticulocyte
count. Each neonate was treated with continuous intensive
phototherapy. All neonates received 1–2 g/kg body weight of
IVIG in intravenous infusion, over no less than 6 hours. Es-
timation of serum bilirubin was done 6 hours after termina-
tion of IVIG infusion and every 12 hours in the next two
days.
The group II of patients included neonates with immune
thrombocytopenia. Laboratory investigations included: full
blood count, standard biochemical analyses, sepsis workup
with determination of C-reactive protein. Abdominal and
cranial ultrasonography was performed in each patient. Indi-
cation for platelet transfusion was platelet count of less than
20 u 10
9/L. All the patients in this group received 1–2 g/kg
body weight of IVIG in intravenous infusion. Platelet count
was repeated 12 and 24 hours after IVIG infusion, and later
during  hospitalization as needed, according to the latest
platelet number. Platelet antigen typization could not be done
since it is not available in our country.
Results
During a 5-year period, 23 neonates received IVIG
during their hospitalization in the NICU. Haemolytic disease
of the newborn was an indication for IVIG treatment in 11
(47.8%) patients, while 12 (52.2%) patients had immune
thrombocytopenia.
In the group of patients with haemolytic disease, 7
(63.6%) patients had OA incompatibility, two (18.2%) OB
incompatibility and two (18.2%) patients had Rh incompati-
bility. The average age on admission was 1.2 days. All the
patients had received phototherapy and one patient had had
ET prior to admission to our NICU. All the neonates had
normal physical examination apart from jaundice. Bilirubin
level on admission ranged from 218 to 347 μmol/L. All the
patients received IVIG (dose 1–2 g/kg body weight), with no
side effects noted. They were all receiving intensive photo-
therapy concomitantly. The average duration of phototherapy
was 40 hours. Two patients needed ET according to their
bilirubin level on admission. When plotted on nomogram for
prediction of risk for exaggerated jaundice 
6, all our patients
were in high risk zone on admission. Twenty-four hours after
IVIG infusion 8 (72.8%) of them were in low intermediate
risk zone, while 2 (18.2%) of them were in high intermediate
risk zone and one (9.0%) patient was in low risk zone, as
shown in Figure 1. Four (33.3%) of the patients received red
blood cell transfusion because of severe anemia. The average
length of hospitalization in this group of patients was 9.0
days.
Fig. 1 – Bilirubin level trend in neonates with haemolytic
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In the group of patients with immune thrombocytope-
nia, two (16.7%) neonates were born to mothers with throm-
bocytopenia due to immune thrombocytopenic purpura
(ITP), whereas 10 (83.3%) patients were born to mothers
with normal platelet count. The average age in this group of
patients was 1.8 days. The platelet count on admission
ranged from 7 to 45 u 10
9/L, with an average being 20.6 u
10
9/L. All the patients had normal physical examination apart
from 8 (66.6%) patients in whom petechiae and/or ecchymo-
ses were noted. Abdominal and cranial ultrasonography per-
formed in each patient showed no signs of bleeding. All pa-
tients were treated with 1g/kg body weight of IVIG for up to
two consecutive days, depending on the response in platelet
count. The administration of IVIG was not associated with
any complications. Three of the patients (25,0%) were put on
corticosteroid treatment for prolonged thrombocytopenia,
which did not resolve after IVIG administration. The average
length of hospitalization was 13.3 days. The average period
until the platelet count reached  100 u 10
9/L was 2, 4 days.
All patients had normal platelet count on their discharge
from hospital, with an average platelet count of 166.9 u
10
9/L.
Discussion
Intravenous immunoglobulin has been successfully
used in treatment of isoimmune haemolytic anemia. Isoim-
mune haemolytic anemia of the newborn is a cause of neo-
natal hyperbilirubinemia due to haemolysis of fetal red blood
cells, caused by transplacentally transmitted maternal anti-
bodies active against antigens present on fetal erythocytes. It
leads to an increased risk of bilirubin encephalopathy and
kernicterus. The therapy is aimed at lowering the serum con-
centration of bilirubin or keeping it from further increase, so
avoiding the levels at which kernicterus may occur. Neonatal
isoimmune haemolytic disease is conventionally treated by
phototherapy and ET 
6. The exact mechanism of action of
IVIG in HDN is still not precisely explained. Intravenous
immunoglobulin is believed to occupy the Fc receptors of
reticuloendothelial cells and prevent further lysis of anti-
body-coated erythrocytes. It is found to decrease hemolysis
leading to reduction in serum bilirubin level 
7–12. There is
subsequently an important decrease in need for exchange
transfusion 
6, 7, 9.
Due to widely used preventive administration of anti-D
prophylaxis in Rhesus-negative women, there is a decrease
in Rhesus sensitization and subsequent haemolytic disease of
the newborn. That is why a high proportion of haemolytic
disease of newborn is nowadays caused by antibodies to
other red blood cell antigens (anti-A, anti-B etc.) 
7. In our
group of patients with haemolytic disease, Rh incompatibil-
ity was the cause of haemolysis in only two (18.2%) patients,
whereas the major cause was OA incompatibility (63.6%).
Many studies have shown that the use of IVIG leads to
a significant reduction in the need for ET 
8–15. Our data also
confirmed that administration of IVIG reduced bilirubin
level, decreasing it beneath the threshold for ET in 8 (66.6%)
patients. Twenty-four hours following IVIG infusion an im-
portant decrease in bilirubin level was observed in most of
our patients (72.8%), diminishing their risk from high to low
intermediate. An infant whose bilirubin level is in low inter-
mediate or low risk zone is at a very low risk to develop se-
vere hyperbilirubinemia 
6. This result goes along with results
of many authors who showed a significant reduction in bili-
rubin level after IVIG use 
8–11. Early administration of IVIG
as soon as the diagnosis of haemolytic anemia is made is
therefore recommended by many authors 
8–11, 13. Monpoux et
al. 
11 suggest that after an initial period of 4 hours of inten-
sive phototherapy, IVIG might be used even in jaundice with
negative Coombs test, mostly caused by ABO incompatibil-
ity.
The average duration of phototherapy in our patients
was 40 hours and the average length of hospitalization was
9.0 days. Although we did not have a control group, the av-
erage length of hospitalization in our HD group is similar to
that of HD group presented by Voto et al. 
16. In a systemic
review by Gottstein and Coone 
8, a reduction in the duration
of phototherapy and hospital stay, when IVIG is used along
with phototherapy for haemolytic disease, is emphasized.
However, there is a great heterogeneity between the studies 
8.
Shortened hospitalization and duration of phototherapy make
a financial benefit which exceeds the cost of IVIG. It is con-
sidered to be a relatively safe product with rarely seen seri-
ous side effects 
7–9, 13. We did not note any immediate ad-
verse effects either.
It is postulated that there is an icreased rate of late
transfusions required in patients treated with IVIG for HDN
8. It is probably secondary to further haemolysis after the ef-
fect of IVIG has expired, so the Fc sites on reticulo-
endothelial cells become free again to bind antibody sensi-
tized neonatal erythrocytes 
7, 8, 11, 13. One of the drawbacks of
our analysis might be the lack of data showing the incidence
of late transfusion rate in HDN group of patients.
Although we realize that the absolute number of our
HDN group is limited, one may notice that our results do not
differ from those of other similar studies 
9, 13.
There are two types of neonatal immune thrombocyto-
penia. Neonatal autoimmune thrombocytopenia is secondary
to transplacental passage of maternal platelet autoantibodies.
It can be seen in neonates born to mother with autoimune
disease, most commonly idiopathic thrombocytopenic pur-
pura (ITP) or systemic lupus eritematodes (SLE). Neonatal
alloimmune thrombocytopenia (NAIT) is caused by maternal
alloimmunisation against fetal platelet antigens inherited
from the father but absent on mother’s platelets. Maternal
anti-platelet antibodies then cross the placenta and destroy
fetal platelets. The majority of casese are caused by antibod-
ies against Human Platelet Antigen 1a – HPA-1a 
17, 18. The
greatest risk of severe thrombocytopenia is intracranial
haemorrhage (ICH), which may cause death or lead to neu-
rological sequelae. Treatment of a neonate with NAIT is
aimed at preventing or stoping thrombocytopenic bleed-
ing 
19, 20. The first therapeutic choise is platelet transfusion 
21.
It is often combined with IVIG, whose administration is as-
sociated with an increase in platelet count, after a period of
24–48h 
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In our group of patients with thrombocytopenia, neo-
natal autoimmune thrombocytopenia was present in 2
(16.7%) patients. It is known that about 10% of neonates of
mothers affected with some autoimmune disease, mostly ITP
and SLE, develop thrombocytopenia 
19. It is a less common
cause of thrombocytopenia than NAIT, as is shown in our
group of patients. Neonatal autoimmune thrombocytopenia is
usually mild. Both of our patients had severe thrombocyto-
penia (  20 u 10
9/L), which is uncommon, but they had no
signs of visceral bleeding and recovered their platelet count
after IVIG administration.
Fetomaternal incompatibility for HPA-1a causes about
75% of all cases of NAIT 
21, 23–26. It is typically diagnosed in
an otherwise well neonate, who develops petechiae and/or
purpura shortly after birth. Thrombocytopenia may also be
noted when a full blood count is checked for sepsis workup
or some other clinical reasons 
17. In our group of patients, 8
(66.6%) of them had petechiae and/or purpura with other-
wise normal physical examination. When there is no possi-
bility to screen blood of the mother and the father, which is
the case in our country, it is of great importance to exclude
other possible causes of thrombocytopenia (TORCH screen-
ing, “blueberry muffin” rash, intrauterine growth restriction,
thrombosis, sepsis, etc). The testing to confirm NAIT would
be performed in order to discover an antibody in the
mother’s plasma directed against a platelet-specific antigen
present in the father, but not in the mother. This is a complex
testing which should be done only in a laboratory with expe-
rience in this field 
17.
If a neonate has low platelet count with no other expla-
nation, so the clinical diagnosis of NAIT is confirmed, the
first therapeutic choice in a bleeding newborn would be a
random donor platelet transfusion if the platelet count is less
than 30 u 10
9/L 
18, 21. Platelet number which presents an indi-
cation for transfusion slightly differs according to the litera-
ture source 
20. Neonates with no signs of bleeding and plate-
let count of more than 30 u 10
9/L should be closely moni-
tored (including repeated platelet count and ultrasound ex-
amination). Many authors believe that in case of severe
thrombocytopenia, the best treatment modality would be to
give random donor platelet transfusion first and then to in-
fuse IVIG and closely follow the platelet count 
17, 20–22. This
is also the strategy accepted by our team. After transfusion of
platelets, when it was indicated, all neonates in our presenta-
tion were infused with IVIG, which was not associated with
any side effects.
Although there is no strong evidence to support the use
of corticosteroids in the treatment of NAIT, some authors
propose the use of methylprednisolone for neonates with
prolonged thrombocytopenia if it persists after IVIG treat-
ment 
17. Three (25%) of our patients were put on a short
course of corticosteroids until their platelet count reached
normal range.
Conclusion
Indications for the use of IVIG in neonates in our
group of patients were haemolytic disease and immune
thrombocytopenia of the newborn. Its use in addition to
phototherapy in treatment of haemolytic disease of the
newborn led to the reduction in the degree of haemolysis
and therefore the need for exchange transfusion. It was also
shown to be effective in increasing the platelet count in
case of immune thrombocytopenia of the newborn. No side
effects of IVIG were noted, so it can be considered a safe
treatment for the newborn.
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